Raymond James analyst Steve Seedhouse reiterated a Strong Buy rating and $40.00 price target on Viking Therapeutic (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Viking Therapeutics (VKTX) Presents New Data from Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol at EASLApril 11, 2019 7:03 AM Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019April 11, 2019 7:02 AM